Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology. (19th May 2022)
- Record Type:
- Journal Article
- Title:
- Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology. (19th May 2022)
- Main Title:
- Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology
- Authors:
- Ueland, Thor
Hausberg, Ingvild
Mørtberg, Trude Victoria
Dahl, Tuva Børresdatter
Lerum, Tøri Vigeland
Michelsen, Annika
Ranheim, Trine
Nezvalova Henriksen, Katerina
Dyrhol-Riise, Anne Ma
Holme, Pål André
Aaløkken, Trond Mogens
Skjønsberg, Ole Henning
Barratt-Due, Andreas
Ahlén, Maria Therese
Aukrust, Pål
Halvorsen, Bente - Abstract:
- Abstract: Thromboembolic events are frequent and associated with poor outcome in severe COVID-19 disease. Anti-PF4/polyanion antibodies are related to heparin-induced thrombocytopenia (HIT) and thrombus formation, but data on these antibodies in unselected COVID-19 populations are scarce. We assessed the presence of anti-PF4/polyanion antibodies in prospectively collected serum from an unselected cohort of hospitalized COVID-19 patients and evaluated if elevated levels could give prognostic information on ICU admission and respiratory failure (RF), were associated with markers of inflammation, endothelial activation, platelet activation, coagulation and fibrosis and were associated with long-term pulmonary CT changes. Five out of 65 patients had anti-PF4/polyanion reactivity with OD ≥0.200. These patients had more severe disease as reflected by ICU admission without any evidence of HIT. They also had signs of enhanced inflammation and fibrinogenesis as reflected by elevated ferritin and osteopontin, respectively, during the first 10 days of hospitalization. Increased ferritin and osteopontin persisted in these patients at 3 months follow-up, concomitant with pulmonary CT pathology. Our finding shows that the presence of anti-PF4/polyanion antibodies in unselected hospitalized COVID−19 patients was not related to HIT, but was associated with disease severity, inflammation, and pulmonary pathology after 3 months.
- Is Part Of:
- Platelets. Volume 33:Number 4(2022)
- Journal:
- Platelets
- Issue:
- Volume 33:Number 4(2022)
- Issue Display:
- Volume 33, Issue 4 (2022)
- Year:
- 2022
- Volume:
- 33
- Issue:
- 4
- Issue Sort Value:
- 2022-0033-0004-0000
- Page Start:
- 640
- Page End:
- 644
- Publication Date:
- 2022-05-19
- Subjects:
- Anti-PF4/polyanion antibodies -- COVID-19 -- HIT -- intensive care unit -- lung
Blood platelets -- Periodicals
Blood Platelets -- Periodicals
615.39 - Journal URLs:
- http://informahealthcare.com/loi/plt ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/09537104.2022.2042238 ↗
- Languages:
- English
- ISSNs:
- 0953-7104
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6537.844500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 21650.xml